论文部分内容阅读
抗体工程药物是生物制药技术领域的重要组成部分之一。随着杂交瘤细胞、基因工程和分子免疫学、抗体库等技术不断建立和完善以及发展和应用,为单克隆抗体药物的制备和规模化、规范化生产奠定了良好的基础,也使抗体药物的研制与应用达到了新的高度。特别是,单克隆抗体药物的特异性高、均质性好、亲和力强、靶向性佳、毒副作用小、疗效确切等特点使其成为当今基因工程药物研究的热点。而老年病因其复杂性、多样性、多系统器质性病变及难治性等特点,在有效的临床药物治疗方面一直是同学科领域关注的焦点和重点。为此,本文将对某些单克隆抗体目前在老年病中的临床研究和应用情况进行综述,并对其未来应用前景和发展方向及其趋势进行展望,期待有些抗体药物能在老年病的临床诊断和治疗上得以广泛应用,也为临床相关老年性疾病的诊断和治疗带来新的希望。
Antibody-engineered drugs are an important part of biopharmaceutical technology. With the continuous establishment and improvement of hybridoma cells, gene engineering and molecular immunology, antibody library and its development and application, it has laid a good foundation for the preparation, large-scale and standardization of monoclonal antibody drugs, Development and application reached a new height. In particular, monoclonal antibody drugs have high specificity, good homogeneity, strong affinity, good targeting, small toxic and side effects, and definite therapeutic effect, which make them become the hotspot of genetic engineering drugs. The elderly due to its complexity, diversity, multiple system organic disease and refractory features such as effective clinical drug treatment has been the focus of attention with the academic field. To this end, this article will review the current clinical research and application of some monoclonal antibodies in geriatric diseases, and look forward to their future application prospects and development trends and trends, and expect some of the antibody drugs in the clinical treatment of geriatric diseases Diagnosis and treatment are widely used, but also for the clinical diagnosis and treatment of senile diseases bring new hope.